LLY-284
Pou rechèch syantifik sèlman, pa pou pasyan yo.
Pwodwi detay
Tags pwodwi
| Gwosè pake | Disponibilite | Pri (USD) |
| 0.1G | Nan Stock | 350 |
| 0.5G | Nan Stock | 750 |
| 1G | Nan Stock | 910 |
Non Chimik:
7H-Pyrrolo[2,3-d]pirimidin-4-amine, 7-[(5S)-5-C-phenyl-β-D-ribofuranosyl]-
Kòd SMILES:
O[C@H]1[C@H](N2C3C(=C(N=CN=3)N)C=C2)O[C@]([H])([C@@H](O) C2C=CC=CC=2)[C@H]1O
Kòd InChi:
InChI=1S/C17H18N4O4/c18-15-10-6-7-21(16(10)20-8-19-15)17-13(24)12(23)14(25-17)11(22) 9-4-2-1-3-5-9/h1-8,11-14,17,22-24H,(H2,18,19,20)/t11-,12-,13+,14+, 17+/m0/s1
InChi kle:
WWOOWAHTEXIWBO-CNUKPYSBSA-N
Mot:
2226515-75-7;CAS:2226515-75-7;CAS:2226515-75-7;LLY-284;LLY 284;LLY284
Solibilite:
Depo:
Deskripsyon:
LLY-283 se yon inibitè efikas nan PRMT5.
Sib: PRMT5


![3-chloro-2-(10-fluoro-8-(prop-1-yn-1-yl)-1,2,3,4,12,12a-hexahydro-6H-benzo[f]pirazino[2,1 -c][1,4]oxazepin-9-yl)fenol](http://www.caerulumpharm.com/uploads/20240722105749.jpg)
![1H-Pyrazolo[3,4-d]pirimidin, 6-chloro-1-[[4-[1-(1-methylethyl)-4-(trifluoromethyl)-1H-imidazol-2-yl]phenyl]methyl]-](http://www.caerulumpharm.com/uploads/20240603134133.jpg)

![4H-1,3-Dioxolo[4,5-c]pyrrole-4-carboxylic asid, tetrahydro-2,2-dimethyl-6-oxo-, (3aS,4S,6aS)-](http://www.caerulumpharm.com/uploads/20241023143839.jpg)

